Mesa Laboratories, Inc. (NASDAQ:MLAB – Get Free Report) Director R Tony Tripeny purchased 900 shares of the firm’s stock in a transaction on Thursday, August 13th. The shares were acquired at an average price of $113.69 per share, for a total transaction of $102,321.00. Following the purchase, the director directly owned 6,298 shares of the company’s stock, valued at approximately $716,019.62. This represents a 16.67% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Mesa Laboratories Trading Up 10.9%
Shares of MLAB stock opened at $119.72 on Thursday. Mesa Laboratories, Inc. has a 52-week low of $58.83 and a 52-week high of $120.45. The stock has a market cap of $670.43 million, a price-to-earnings ratio of 142.53 and a beta of 0.92. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.32 and a current ratio of 1.79. The firm has a fifty day moving average of $100.85 and a 200-day moving average of $96.75.
Mesa Laboratories (NASDAQ:MLAB – Get Free Report) last issued its earnings results on Monday, August 10th. The medical instruments supplier reported $2.68 earnings per share for the quarter. The business had revenue of $60.14 million for the quarter. Mesa Laboratories had a net margin of 1.92% and a return on equity of 22.72%.
Mesa Laboratories Dividend Announcement
Wall Street Analyst Weigh In
MLAB has been the subject of a number of analyst reports. Wells Fargo & Company lifted their price objective on Mesa Laboratories from $94.00 to $110.00 and gave the company an “equal weight” rating in a report on Friday, August 14th. Wall Street Zen cut shares of Mesa Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 15th. Finally, Weiss Ratings raised shares of Mesa Laboratories from a “sell (d)” rating to a “hold (c-)” rating in a report on Tuesday, August 11th. Three equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, Mesa Laboratories has an average rating of “Hold” and a consensus price target of $110.00.
View Our Latest Stock Analysis on Mesa Laboratories
Institutional Investors Weigh In On Mesa Laboratories
Hedge funds have recently added to or reduced their stakes in the stock. Northwestern Mutual Wealth Management Co. raised its position in Mesa Laboratories by 5,366.7% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 328 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 322 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Mesa Laboratories in the 4th quarter valued at $27,000. Kestra Advisory Services LLC bought a new stake in shares of Mesa Laboratories during the fourth quarter worth $55,000. BNP Paribas Financial Markets raised its position in shares of Mesa Laboratories by 115.3% during the second quarter. BNP Paribas Financial Markets now owns 786 shares of the medical instruments supplier’s stock worth $74,000 after acquiring an additional 421 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its position in Mesa Laboratories by 432.9% in the second quarter. Tower Research Capital LLC TRC now owns 842 shares of the medical instruments supplier’s stock worth $79,000 after purchasing an additional 684 shares during the period. Institutional investors own 90.60% of the company’s stock.
About Mesa Laboratories
Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.
The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.
Featured Stories
- Five stocks we like better than Mesa Laboratories
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
